Intact Therapeutics develops smart gels for localized drug delivery targeting gastrointestinal diseases, utilizing advanced polymer technology to enhance drug absorption in the gut. This approach addresses the limitations of systemic treatments by providing targeted therapy, improving efficacy and minimizing side effects for patients.
Funding
$645K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BVNSNASLFounders
Product
Problem
Current systemic drug delivery methods for gastrointestinal diseases often result in widespread drug distribution, leading to reduced efficacy and increased side effects due to off-target effects. This lack of targeted drug delivery limits the therapeutic potential and increases the burden on patients.
Solution
Intact Therapeutics is developing smart gels for localized drug delivery within the gastrointestinal tract, addressing the limitations of systemic treatments. These gels utilize advanced polymer technology to enhance drug absorption specifically in the gut, ensuring targeted therapy. By delivering drugs directly to the affected area, Intact Therapeutics aims to improve treatment efficacy while minimizing systemic side effects. This targeted approach offers a more efficient and patient-friendly solution for managing gastrointestinal diseases.
Target Audience
The primary target audience includes patients suffering from gastrointestinal diseases and pharmaceutical companies seeking innovative drug delivery methods.
Features
- Smart gel formulation for targeted drug release in the GI tract
- Advanced polymer technology to enhance drug absorption
- Localized drug delivery to minimize systemic side effects